Soybean-derived recombinant human epidermal growth factor protects against experimental necrotizing enterocolitis

Area of Science:

• Gastroenterology
• Biotechnology
• Neonatal Research

Background:

• Epidermal Growth Factor (EGF) is known to reduce necrotizing enterocolitis (NEC).
• High cost of clinical EGF limits its use.
• Soybean-expressing human EGF was developed as a cost-effective alternative.

Purpose of the Study:

• To evaluate the effectiveness of soybean-derived EGF in an experimental model of NEC.
• To determine the optimal dosage of soybean-derived EGF for NEC treatment.
• To investigate the molecular mechanisms underlying the protective effects of soybean-derived EGF.

Main Methods:

• Newborn rats were exposed to a NEC-inducing regimen (formula feeding and hypoxia).
• Formula was supplemented with extract from EGF-expressing or empty soybeans.
• NEC pathology, tight junction protein localization (JAM-A, ZO-1), and gene expression (COX-2, iNOS) were analyzed.

Main Results:

• A dose of 75μg/kg/day EGF from soybean extract was well tolerated and significantly decreased NEC scores.
• Soybean-derived EGF attenuated the dissociation of JAM-A and ZO-1 proteins.
• Intestinal expression of COX-2 and iNOS mRNAs was reduced by soybean-derived EGF.

Conclusions:

• Supplementation with soybean-expressed EGF significantly reduced NEC in a rat model.
• Soybean-derived EGF demonstrates potential as an economical strategy for NEC prophylaxis.
• This approach could make EGF administration more accessible for clinical NEC prevention.